International Clinical Trial: Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade

Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07130032) titled 'Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade' on Aug. 14.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: EuroCityClinic LLC

Condition: Metastatic Non-small Cell Lung Cancer (NSCLC) Metastatic Cutaneous Melanoma

Intervention: Combination Product: reICB regimen (NSCLC)

Recruitment Status: Recrui...